Recently, IDH inhibitors have been identified as targeted therapies, and ivosidenib (IDH1 inhibitor) [40] and enasidenib (IDH2 inhibitor) [41] have shown promising results in patients with relapsed or refractory AML. This evidence concerns the gene IDH1 and acute myeloid leukemia.